Sentences with phrase «vaccine immunogenicity»

The Transcriptomics Core Facility supports a systems biology approach in vaccine development focusing on the identification of transcriptomic correlates of vaccine immunogenicity and efficacy for a range of novel and licensed vaccines using PBMC or whole - blood and BAL fluid samples.

Expertise concerns vaccine immunogenicity, vaccine efficacy and infectious disease pathogenesis.

«Early blood signatures of vaccine immunogenicity.»

Not exact matches

Secondly, it helps improve the immunogenicity of some vaccines, which is the body's ability to produce antibodies against the antigen for which the vaccine has been given.

The trial at BIDMC is evaluating three different ZPIV dosing schedules, while the trial at Saint Louis University is evaluating the safety and immunogenicity of three different vaccine doses.

Flor M. Munoz, M.D., of the Baylor College of Medicine, Houston, and colleagues randomly assigned 48 women to receive the Tdap vaccine (n = 33) or placebo (n = 15) at 30 to 32 weeks» gestation to evaluate the safety and immunogenicity (ability to produce an immune response) of the vaccine administered during pregnancy.

The study, which was published in the last issue of Science Translational Medicine, reports early plasma cytokine signatures that correlate with, and predict, the immunogenicity and reactogenicity of the vaccine.

The European research collaboration behind this study focuses on deep immunological analysis of the immunogenicity and reactogenicity of the Ebola vaccine in healthy volunteers.

«Safety, immunogenicity of two doses of the HPV - 16 / 18 AS04 adjuvanted vaccine Cervarix.»

White MT, Verity R, Griffin JT, et al.White MT, Verity R, Griffin JT, Asante KP, Owusu - Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC close, 2015, Immunogenicity of the RTS, S / AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infectious Diseases, Vol: 15, ISSN: 1473 - 3099, Pages: 1450 - 1458

The next steps for this vaccine are to produce a clinical grade lot and conduct a phase 1 study of safety and immunogenicity in infants, Moore says.

Next to this, WBVR offers the use of its infrastructure to perform immunogenicity and efficacy studies for newly developed vaccines.

Selected mucosal vaccine candidates will be tested for immunogenicity in mice.

Such models are valuable for the analysis of parameters associated with vaccine safety, immunogenicity, delivery and protection as NHPs replicate key features of the human immune response more faithfully than any other animal model.

TNA8: BPRC will provide access to macaques for immunogenicity / adjuvanticity evaluation of vaccine candidates for malaria, tuberculosis, HIV, influenza, West Nile virus or dengue virus, with up to three (prime - boost) immunisation events.

The HZI will also not only perform experiments to compare the predictive immunogenicity and efficacy of vaccines between different model species and humans but will test comparative effects of adjuvants.

The clinical research center CAIMED, part of Ponce Health Sciences University in Puerto Rico, will examine the vaccine's safety and immunogenicity in participants who have already been naturally exposed to Zika or dengue viruses

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS.

We will evaluate the immunogenicity of vaccine candidates (provided by user) administered by systemic, transdermal or mucosal routes and will monitor humoral responses and cellular responses.

Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV - 1 subtype C gp145 envelope for use in preclinical and clinical vaccine research, doi: 10.1128 / JVI.00412 - 15, J Virol.

The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.

The Walter Reed Army Institute of Research (WRAIR) began vaccinations today in a Phase 1 human clinical trial to test the safety and immunogenicity of the Zika purified inactivated virus (ZPIV) vaccine.

CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.

In April 2017, Moderna published human data for its mRNA vaccine technology in Molecular Therapy, which showed that its first prophylactic vaccine candidate, mRNA - 1440 — an mRNA prophylactic vaccine against avian H10N8 influenza — induced high levels of immunogenicity and was safe and well tolerated.

Vaccine studies in infants < 6 mo with novel vaccine candidates have generally demonstrated poor immunogenicitVaccine studies in infants < 6 mo with novel vaccine candidates have generally demonstrated poor immunogenicitvaccine candidates have generally demonstrated poor immunogenicity (90).

The development track will begin with a Phase I trial to test the vaccine regimen's safety and immunogenicity and depending on those study results, a larger efficacy study will follow.

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Citation: Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, et al. (2010) Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial.

The vaccines were evaluated for immunogenicity and efficacy; however, because of the previous report of immunopathology on challenge of ferrets and nonhuman primates that had been vaccinated with a whole virus adjuvanted vaccine and mice that had been vaccinated with a VLP vaccine, the primary orientation was to assess for immunopathology among animals in relation to type of vaccine, dosage, serum antibody responses, and virus infection.

However, until an AMA1 malaria vaccine demonstrates clinical efficacy against genetically diverse natural parasites, the relevance of growth inhibition assays and other humoral and cellular immunogenicity endpoints for clinical development decisions will remain a matter of reasoned conjecture.

MHRP researchers describe the safety and immunogenicity of a multiclade DNA vaccine prime with a muticlade recombinant adenovirus serotype 5 (rAd5) boost

Finding comparable safety and immunogenicity in U.S. and Ugandan populations provided proof of principle that a protective, multivalent filovirus vaccine is attainable.

RV 172: A Phase I / II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV - 1 DNA Plasmid Vaccine, VRC - HIVDNA016 -00-VP, Boosted by a Multiclade HIV - 1 Recombinant ADENOVIRUS - 5 Vector Vaccine, VRC - HIVADV014 -00-VP in HIV Uninfected Adu

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA - 1440, Induces High Levels of Immunogenicity

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime - boost Ebola vaccine regimen in both healthy and HIV - infected volunteers.

Along with collaborators, the Weiner Lab was the first to move DNA vaccines to human clinical studies, establishing their initial safety and immunogenicity.

Within the framework of TRANSVAC2, the HZI will offer access in the form of pre-clinical studies in the murine system to assess the immunogenicity, safety and efficacy of specific vaccine formulations.

As partner of TRANSVAC, IRTA will provide access to their animal facilities (CReSA) to carry out safety and immunogenicity studies of new candidate vaccines and / or of novel vaccination (administration) strategies in pigs, ferrets and other large animal species.

Immunogenicity of ALVAC - HIV (vCP1521) and AIDSVAX B / E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial

Duration of one vaccine safety and immunogenicity profiling experiment is maximally 26 weeks.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.

Once recombinant vaccine antigens produced by this service are available, they could be forwarded to Analytical services (TNA3), Adjuvants and delivery systems (TNA2) or Immunogenicity and efficacy studies (TNA8), if applicable.

Progression of TB vaccines through the discovery, pre-clinical and clinical stages of development requires demonstration of safety, immunogenicity and the ability to reduce or prevent TB disease.

As partner of TRANSVAC2, WBVR will provide access to their animal facilities (Lelystad) to carry out immunogenicity and efficacy studies of new candidate vaccines and / or of novel vaccination (administration) strategies in pigs, cattle, ferrets or other animal species.

Within the framework of TRANSVAC2, the HZI will offer access in the form of pre-clinical studies in the murine system to assess the immunogenicity, safety and efficacy of specific vaccine formulations containing a mucosal adjuvant.

Non-structural protein 1 (NS1) truncated (NS1 - 126, NS1 - 99 and NS1 - 73) or deleted (DNS1) H3N8 canine influenza viruses (CIVs) were tested for their safety, immunogenicity and protection efficacy as live - attenuated influenza vaccines (LAIVs) against wild - type (WT) H3N8 CIV.

-- «Mammaglobin — A Immunogenicity in Canine Mammary Cancer Vaccine Development,» led by Dr. R. Curtis Bird, Department of Pathobiology.

Notably, immunogenicity and protection efficacy conferred by the NS1 mutant H3N8 CIVs was better than that observed with a CIV H3N8 inactivated influenza vaccine (IIV).

Moreover, a single intranasal immunization dose showed higher immunogenicity and protection than that conferred with a commercial inactivated vaccine, making our live - attenuated CIV an excellent vaccine candidate for the prevention and control of CIV in dogs.

Le, T.P., Church, L.W.P., Corradin, G., Hunter, R.L., Charoenvit, Y., Wang, R., de la Vega, P., Sacci, J., Ballou, W.R., Kolodny, N., Kitov, S., Glenn, G.M., Richards, R. L., Alving, C.R., Hoffman, S.L. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.